Latest News and Press Releases

Alkeus Pharmaceuticals presents gildeuretinol data during the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting May 4-8, 2025

Alkeus Pharmaceuticals, Inc. receives FDA Rare Pediatric Disease and Fast Track designations for gildeuretinol as a treatment for Stargardt Disease

Alkeus Pharmaceuticals, Inc., today announced that results from its study of gildeuretinol in geographic atrophy were presented at AAO 2024.

Alkeus Pharmaceuticals appoints Tamara Dillon as Chief Human Resources Officer

Alkeus Pharmaceuticals, Inc. announced today that Michel Dahan has joined the company as President and Chief Executive Officer.

Alkeus Pharmaceuticals announces interim data demonstrating no signs of disease progression in early-stage Stargardt patients treated with gildeuretinol.

Alkeus Pharmaceuticals Announces Presentation of Positive Gildeuretinol Data in Early-Stage Stargardt Patients During the ARVO 2024 Annual Meeting May 5-9

All three patients treated for two years or more have remained free of symptoms and disease progression while taking gildeuretinol.TEASE-3 is the first clinical trial in early-stage Stargardt disease,...

CAMBRIDGE, Mass., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that Joshua Boger, Ph.D., Executive Chairman, and Leonide Saad, Ph.D., President and Chief Executive...

Primary endpoint met, demonstrating a 21% slowing (p<0.001) in the growth rate of atrophic retinal lesions compared to the untreated arm; 28% reduction (p<0.001) using observed atrophic...